000266761 001__ 266761
000266761 005__ 20240403113329.0
000266761 0247_ $$2pmc$$apmc:PMC10840378
000266761 0247_ $$2doi$$a10.1161/STROKEAHA.123.044281
000266761 0247_ $$2pmid$$apmid:38134264
000266761 0247_ $$2ISSN$$a0039-2499
000266761 0247_ $$2ISSN$$a1524-4628
000266761 0247_ $$2altmetric$$aaltmetric:157725337
000266761 037__ $$aDZNE-2024-00024
000266761 041__ $$aEnglish
000266761 082__ $$a610
000266761 1001_ $$00000-0002-3376-5822$$aO'Keefe, James H$$b0
000266761 245__ $$aOmega-3 Blood Levels and Stroke Risk: A Pooled and Harmonized Analysis of 183 291 Participants From 29 Prospective Studies.
000266761 260__ $$aPhiladelphia, Pa.$$bLippincott Williams & Wilkins$$c2024
000266761 3367_ $$2DRIVER$$aarticle
000266761 3367_ $$2DataCite$$aOutput Types/Journal article
000266761 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1705486344_18421
000266761 3367_ $$2BibTeX$$aARTICLE
000266761 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000266761 3367_ $$00$$2EndNote$$aJournal Article
000266761 520__ $$aThe effect of marine omega-3 PUFAs on risk of stroke remains unclear.We investigated the associations between circulating and tissue omega-3 PUFA levels and incident stroke (total, ischemic, and hemorrhagic) in 29 international prospective cohorts. Each site conducted a de novo individual-level analysis using a prespecified analytical protocol with defined exposures, covariates, analytical methods, and outcomes; the harmonized data from the studies were then centrally pooled. Multivariable-adjusted HRs and 95% CIs across omega-3 PUFA quintiles were computed for each stroke outcome.Among 183 291 study participants, there were 10 561 total strokes, 8220 ischemic strokes, and 1142 hemorrhagic strokes recorded over a median of 14.3 years follow-up. For eicosapentaenoic acid, comparing quintile 5 (Q5, highest) with quintile 1 (Q1, lowest), total stroke incidence was 17% lower (HR, 0.83 [CI, 0.76-0.91]; P<0.0001), and ischemic stroke was 18% lower (HR, 0.82 [CI, 0.74-0.91]; P<0.0001). For docosahexaenoic acid, comparing Q5 with Q1, there was a 12% lower incidence of total stroke (HR, 0.88 [CI, 0.81-0.96]; P=0.0001) and a 14% lower incidence of ischemic stroke (HR, 0.86 [CI, 0.78-0.95]; P=0.0001). Neither eicosapentaenoic acid nor docosahexaenoic acid was associated with a risk for hemorrhagic stroke. These associations were not modified by either baseline history of AF or prevalent CVD.Higher omega-3 PUFA levels are associated with lower risks of total and ischemic stroke but have no association with hemorrhagic stroke.
000266761 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000266761 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000266761 650_7 $$2Other$$aatrial fibrillation
000266761 650_7 $$2Other$$acerebrovascular disease
000266761 650_7 $$2Other$$afish
000266761 650_7 $$2Other$$afish oil
000266761 650_7 $$2Other$$astroke
000266761 650_7 $$0AAN7QOV9EA$$2NLM Chemicals$$aEicosapentaenoic Acid
000266761 650_7 $$025167-62-8$$2NLM Chemicals$$aDocosahexaenoic Acids
000266761 650_7 $$2NLM Chemicals$$aFatty Acids, Omega-3
000266761 650_2 $$2MeSH$$aHumans
000266761 650_2 $$2MeSH$$aProspective Studies
000266761 650_2 $$2MeSH$$aEicosapentaenoic Acid
000266761 650_2 $$2MeSH$$aDocosahexaenoic Acids
000266761 650_2 $$2MeSH$$aHemorrhagic Stroke: epidemiology
000266761 650_2 $$2MeSH$$aFatty Acids, Omega-3
000266761 650_2 $$2MeSH$$aStroke: epidemiology
000266761 650_2 $$2MeSH$$aIschemic Stroke
000266761 650_2 $$2MeSH$$aRisk Factors
000266761 7001_ $$aTintle, Nathan L$$b1
000266761 7001_ $$aHarris, William S$$b2
000266761 7001_ $$00000-0002-2746-2323$$aO'Keefe, Evan L$$b3
000266761 7001_ $$aSala-Vila, Aleix$$b4
000266761 7001_ $$00000-0001-9800-1308$$aAttia, John$$b5
000266761 7001_ $$00000-0003-0514-0865$$aGarg, G Manohar$$b6
000266761 7001_ $$00000-0003-2225-0986$$aHure, Alexis$$b7
000266761 7001_ $$00000-0001-5233-2902$$aBork, Christian Sørensen$$b8
000266761 7001_ $$00000-0002-0623-5666$$aSchmidt, Erik Berg$$b9
000266761 7001_ $$aVenø, Stine Krogh$$b10
000266761 7001_ $$00000-0003-4979-8351$$aChien, Kuo-Liong$$b11
000266761 7001_ $$00000-0001-7009-7838$$aChen, Yun-Yu Amelia$$b12
000266761 7001_ $$aEgert, Sarah$$b13
000266761 7001_ $$aFeldreich, Tobias Rudholm$$b14
000266761 7001_ $$00000-0002-6933-4637$$aÄrnlöv, Johan$$b15
000266761 7001_ $$00000-0003-2335-8542$$aLind, Lars$$b16
000266761 7001_ $$00000-0002-5041-248X$$aForouhi, Nita G$$b17
000266761 7001_ $$00000-0001-7638-0589$$aGeleijnse, Johanna M$$b18
000266761 7001_ $$00000-0003-2861-9051$$aPertiwi, Kamalita$$b19
000266761 7001_ $$00000-0002-6841-8396$$aImamura, Fumiaki$$b20
000266761 7001_ $$00000-0003-3414-6983$$ade Mello Laaksonen, Vanessa$$b21
000266761 7001_ $$00000-0001-6052-2001$$aUusitupa, W Matti$$b22
000266761 7001_ $$00000-0002-3424-0745$$aTuomilehto, Jaakko$$b23
000266761 7001_ $$00000-0002-3394-7749$$aLaakso, Markku$$b24
000266761 7001_ $$00000-0002-9158-283X$$aLankinen, Maria Anneli$$b25
000266761 7001_ $$00000-0001-5032-2452$$aLaurin, Danielle$$b26
000266761 7001_ $$00000-0002-5324-862X$$aCarmichael, Pierre-Hugues$$b27
000266761 7001_ $$aLindsay, Joan$$b28
000266761 7001_ $$00000-0002-1404-9222$$aLeander, Karin$$b29
000266761 7001_ $$00000-0003-3551-1348$$aLaguzzi, Federica$$b30
000266761 7001_ $$00000-0002-4176-8273$$aSwenson, Brenton R$$b31
000266761 7001_ $$aLongstreth, William T$$b32
000266761 7001_ $$00000-0002-9426-7595$$aManson, JoAnn E$$b33
000266761 7001_ $$00000-0001-6283-0980$$aMora, Samia$$b34
000266761 7001_ $$00000-0002-9705-0842$$aCook, Nancy R$$b35
000266761 7001_ $$00000-0002-3320-796X$$aMarklund, Matti$$b36
000266761 7001_ $$0P:(DE-2719)2811697$$aMelo van Lent, Debora$$b37
000266761 7001_ $$00000-0003-4383-5641$$aMurphy, Rachel$$b38
000266761 7001_ $$00000-0001-5696-0084$$aGudnason, Vilmundur$$b39
000266761 7001_ $$aNinomiya, Toshihara$$b40
000266761 7001_ $$aHirakawa, Yoichiro$$b41
000266761 7001_ $$00000-0002-5579-3410$$aQian, Frank$$b42
000266761 7001_ $$00000-0002-8480-1563$$aSun, Qi$$b43
000266761 7001_ $$00000-0002-8233-6274$$aHu, Frank$$b44
000266761 7001_ $$00000-0003-4599-2245$$aArdisson Korat, Andres V$$b45
000266761 7001_ $$00000-0002-8620-4586$$aRisérus, Ulf$$b46
000266761 7001_ $$00000-0002-6172-9845$$aLázaro, Iolanda$$b47
000266761 7001_ $$aSamieri, Cecilia$$b48
000266761 7001_ $$00000-0003-2848-6287$$aLe Goff, Mélanie$$b49
000266761 7001_ $$aHelmer, Catherine$$b50
000266761 7001_ $$00000-0002-9028-0290$$aSteur, Marinka$$b51
000266761 7001_ $$00000-0003-2830-6813$$aVoortman, Trudy$$b52
000266761 7001_ $$00000-0003-0173-9571$$aIkram, M Kamran$$b53
000266761 7001_ $$aTanaka, Toshiko$$b54
000266761 7001_ $$aDas, Jayanta K$$b55
000266761 7001_ $$00000-0002-6273-1613$$aFerrucci, Luigi$$b56
000266761 7001_ $$aBandinelli, Stefania$$b57
000266761 7001_ $$00000-0001-7553-3408$$aTsai, Michael$$b58
000266761 7001_ $$00000-0002-0956-9821$$aGuan, Weihua$$b59
000266761 7001_ $$00000-0002-6482-2711$$aGarg, Parveen$$b60
000266761 7001_ $$00000-0003-2134-4227$$aVerschuren, W M Monique$$b61
000266761 7001_ $$00000-0002-9714-4304$$aBoer, Jolanda M A$$b62
000266761 7001_ $$00009-0001-2062-8810$$aBiokstra, Anneke$$b63
000266761 7001_ $$00000-0002-0648-999X$$aVirtanen, Jyrki$$b64
000266761 7001_ $$0P:(DE-2719)2000057$$aWagner, Michael$$b65
000266761 7001_ $$aWestra, Jason$$b66
000266761 7001_ $$aAlbuisson, Luc$$b67
000266761 7001_ $$00000-0003-3301-5519$$aYamagishi, Kazumasa$$b68
000266761 7001_ $$00000-0003-0461-175X$$aSiscovick, David S$$b69
000266761 7001_ $$00000-0002-7038-1844$$aLemaitre, Rozenn N$$b70
000266761 7001_ $$00000-0001-7958-9492$$aMozaffarian, Dariush$$b71
000266761 773__ $$0PERI:(DE-600)1467823-8$$a10.1161/STROKEAHA.123.044281$$gVol. 55, no. 1, p. 50 - 58$$n1$$p50 - 58$$tStroke$$v55$$x0039-2499$$y2024
000266761 8564_ $$uhttps://pub.dzne.de/record/266761/files/DZNE-2024-00024_Restricted.pdf
000266761 8564_ $$uhttps://pub.dzne.de/record/266761/files/DZNE-2024-00024_Restricted.pdf?subformat=pdfa$$xpdfa
000266761 909CO $$ooai:pub.dzne.de:266761$$pVDB
000266761 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000057$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b65$$kDZNE
000266761 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000266761 9141_ $$y2024
000266761 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2023-08-25$$wger
000266761 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSTROKE : 2022$$d2023-08-25
000266761 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000266761 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000266761 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000266761 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-25
000266761 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000266761 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000266761 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-25
000266761 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-25
000266761 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000266761 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000266761 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bSTROKE : 2022$$d2023-08-25
000266761 9201_ $$0I:(DE-2719)1011201$$kAG Wagner$$lNeuropsychology$$x0
000266761 980__ $$ajournal
000266761 980__ $$aVDB
000266761 980__ $$aI:(DE-2719)1011201
000266761 980__ $$aUNRESTRICTED